THE ROSEN LAW FIRM, P.A.

Laurence M. Rosen

Phillip Kim

Jing Chen

Daniel Tyre-Karp

Robin Howald

275 Madison Ave, 40th Floor

New York, New York 10016

Telephone: (212) 686-1060

Fax: (212) 202-3827

Email: lrosen@rosenlegal.com

philkim@rosenlegal.com jchen@rosenlegal.com dtyrekarp@rosenlegal.com rhowald@rosenlegal.com

Lead Counsel for Plaintiffs and the Proposed Class

# UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

IN RE DIDI GLOBAL INC. SECURITIES LITIGATION

21-CV-5807 (LAK)(VF)

Master Docket

This Document Related To: All Actions

MEMORANDUM OF LAW IN FURTHER SUPPORT OF CLASS CERTIFICATION, RESPONDING TO DEFENDANTS' SUR-REPLY

**CLASS ACTION** 

ORAL ARGUMENT REQUESTED

#### I. THE EVIDENCE SUBMITTED SUPPORTS THE PROPOSED CLASS PERIOD

Defendants ask the Court to reduce the 22-day class period to 6 days without submitting the evidence required to support both their assertion that all curative information was disclosed by the market open on July 6 *and* that the statistically-significant 29.9% price decline at the end of the class period, *following* news that PRC authorities might force DiDi to delist from the NYSE, was unrelated to their fraud.

The Court previously accepted this loss causation theory:

"[DiDi's] rationale seems to be that the post-IPO events plaintiffs identify as having revealed the omitted risk of going public—*i.e.*, the CAC's sanctioning of Didi—was not 'new information .... This argument fails .... where, as here, the full contours of the allegedly fraudulent omission emerged in dribs and drabs." ECF 158 at 51-52 (emphasis in original).

As Plaintiffs have shown with evidence (ECF 355 at 13-14, ECF 355-1 at 2-6, 9 and ECF 355-2 at 18-19, 32-35), in light of the CAC's further "sanctioning of DiDi" over the next few weeks—i.e., 25 apps removed from apps stores and super-apps, seven-agency on-site probe, possible forced delisting—and a statistically-significant 29.9% price drop at the end of the class period, whether the July 4-6 news was fully curative is a question for summary judgment or trial. Criticism of the method of calculating retardation of price decline on and after July 6 is different from proving inflation was dissipated by fully curative news by July 6.

The only legal purpose for which an underwriter may engage in stabilizing transactions is

<sup>&</sup>lt;sup>1</sup> Transcript of the Deposition of Terrence Hendershott, Ph.D., taken May 28, 2025 ("Hendershott Tr.") at 24:25–25:8; 131:21-132:14 (Ex. F to the Declaration of Laurence M. Rosen ("Rosen Decl.")).


<sup>&</sup>lt;sup>2</sup> Hendershott Tr. 208:4-20.

to prevent or retard a decline in the share price. <sup>3</sup>
In In re Allstate Corp.
Secs. Litig., 2020 WL 7490280 (N.D. Ill. Dec. 21, 2020), defendants argued that no new news had
been revealed at the end of the class period, and, consequently, its expert "did not perform any

Secs. Litig., 2020 WL 7490280 (N.D. III. Dec. 21, 2020), defendants argued that no new news had been revealed at the end of the class period, and, consequently, its expert "did not perform any empirical testing" concerning the cause of the 10% drop at the end of the class period. *Id.* at \*5. The court found this failure "fatal to defendants' attempts to defeat class certification." *Id.* Defendants were required to submit evidence that news released by the morning of July 6 had a fully curative effect. As they twice declined to do so, there is no basis to shorten the class period.

<sup>3</sup> 17 CFR § 242.104(b) ("Stabilizing is prohibited except for the purpose of preventing or retarding a decline in the market price of a security."); see Billing v. Credit Suisse First Boston Ltd., 426 F.3d 130, 139-40 (2d Cir. 2005), rev'd on other grounds sub nom. Credit Suisse Sec. (USA) LLC v. Billing, 551 U.S. 264, 127 S. Ct. 2383 (2007) (so holding).

## II. DR. AGGARWAL'S ANALYTICAL METHODS ARE RELIABLE



<sup>&</sup>lt;sup>4</sup> The Court-authorized (ECF 353 at 2) Rebuttal Report of Rajesh Aggarwal, Ph.D., dated June 6, 2025 ("Aggarwal Reb."), is attached as Ex. G to the Rosen Decl.

<sup>&</sup>lt;sup>6</sup> Defendants criticized Dr. Aggarwal's initial report (ECF 377 at 3 n.1) because it was not based on more detailed trading data — data the Underwriters willfully withheld for many months. *See* Rosen Decl. at ¶¶3-20 & Exs. A-E.

# THE ROSEN LAW FIRM, P.A.

By: /s/Laurence Rosen

Laurence M. Rosen Phillip Kim Jing Chen Daniel Tyre-Karp Robin Howald 275 Madison Ave, 40th Floor New York, New York 10016 Telephone: (212) 686-1060

Fax: (212) 202-3827

Email: lrosen@rosenlegal.com philkim@rosenlegal.com jchen@rosenlegal.com dtyrekarp@rosenlegal.com rhowald@rosenlegal.com

Counsel for Plaintiffs and the Proposed Class

and

## **GLANCY PRONGAY & MURRAY LLP**

Gregory Linkh 30 Park Ave, Suite 358 New York, NY10169 Telephone: (212) 682-5340

Fax: (212) 884-0988

Email: glinkh@glancylaw.com

and

Kara Wolke Leanne Heine Solish 1925 Century Park East **Suite 2100** Los Angeles, CA 90067

Phone: 310-201-9150

Additional Counsel for Plaintiffs

# **CERTIFICATE OF SERVICE**

I hereby certify that on June 6, 2025, a true and correct copy of the foregoing document was served by CM/ECF to the parties registered to the Court's CM/ECF system.

/s/ Laurence M. Rosen